

Zeqmelit®

Simplifying life for people with severe allergies



Great medical need for **better** allergy treatment

- ✓ Zeqmelit® is a quick and easy treatment for severe to acute allergic reactions
- ✓ In the EU and the US alone, 25–30 million people are diagnosed with moderate to acute allergies
- ✓ Market size \$3.1 billion*
- ✓ There is a need for an easily accessible and effective treatment for severe or acute allergic reactions
- ✓ The treatments that exist today are difficult to give


*Source: Datamonitor Immunotherapy Market Outlook



Milestones achieved

- ✓ **Sales started** in Sweden, Norway, Finland & Denmark
- ✓ **Strong cash after oversubscribed issue**
- ✓ **Letter of intent signed** regarding the Middle East & Gulf countries
- ✓ **Granted SME status** by the European Medicines Agency (EMA)
- ✓ **Exempt from application fee** by the US agency FDA
- ✓ **Submitted iPSP application** to FDA
- ✓ **Agreement with pharmaceutical manufacturer** Adhex Pharma for commercial and large-scale production of Zeqmelit
- ✓ **Follow-on order** for the Nordic market
- ✓ **Trademark protection** for Zeqmelit® in Europe, USA, China, Japan, India, Australia, UK and Canada
- ✓ **Mouth film patented** in over 30 countries incl. Europe, USA, China and Japan
- ✓ **Good results** in the Phase IV study





Severe allergic reaction

A severe rapid hypersensitivity reaction, usually to a special substance such as peanuts, hazelnuts, shellfish, fish, soy, milk, pollen, eggs, and certain medicines, as well as to wasp stings or bee stings.

Can involve:

- Difficulty breathing
- Swelling of the mouth, tongue, throat
- Stomach pain, bloating, vomiting and diarrhoea
- Skin rash, hives
- Low blood pressure
- Disorientation
- In severe cases, it can lead to anaphylactic shock

Existing tablet treatment is complicated and **time-consuming** in an emergency

In connection with an acute allergic reaction, you will need:



Squeeze a large number of tablets out of a blister pack



Crush them



Have access to clean water to pour into the glass



Wait for the tablets to dissolve in the water




Drink



Zeqmelit® shortens the time to treatment

- ✓ Zeqmelit® – in a package as small as a business card
- ✓ A film is a whole dose
- ✓ Easy administration, no need for medical staff or water
- ✓ Placed on the tongue, dissolves within 15 seconds and cannot be spit out
- ✓ Dexamethasone is a well-known and widely used glucocorticoid in acute and severe allergic reactions, croup in children, CINV, and COVID-19

Zeqmelit® is approved for the treatment of acute and severe allergic reactions, croup in children, CINV and for patients with COVID-19 with breathing difficulties and need for supplemental oxygen therapy.



What do **doctors** say?

- ✓ **9 out of 10** doctors would prescribe Zeqmelit® if it was on the market
- ✓ **> 80%** of doctors would prescribe Zeqmelit® to up to 50% of their patients
- ✓ **Very good reception** of doctors as Unimedic Pharma held several well-attended information meetings with asthma and allergy doctors in connection with the launch

"From my perspective as a physician and allergist, I have to say that Zeqmelit is a user-friendly drug. It's easy to carry with you, which is very important. Unfortunately, relatively many people who use tablets do not have these with them because they think it is too complicated."

— Bahram Javizan, Principal investigator, physician and allergist





What do **patients** say?

- ✓ **>70%** of patients would prefer mouth film over tablet treatment
- ✓ **24 %** of patients had had difficulty swallowing in the event of a severe allergic reaction
- ✓ **41 %** of patients had feared for their lives in the event of a severe allergic reaction
- ✓ **68 %** of patients had to seek emergency medical care
- ✓ **Willingness to pay SEK 574 per treatment** according to a study* on how allergy sufferers evaluate their treatment. Price for Zeqmelit® is about 150 SEK per mouth film

*Source: Study from 2022 on how allergy patients evaluate their treatment, published in the World Allergy Organization Journal.

Strong patent and trademark protection



Granted patent applications in Europe, USA, Canada, Brazil, China and Japan



Active patent and trademark protection strategy, Zeqmelit® registered trademark in the EU, Norway, UK, Switzerland, Australia, India, Israel, China, Japan, USA and Canada



Granted patents in more than 30 countries, providing protection until 2035



Upcoming **milestones**

- **Additional trade agreements** in leading European countries
- **Market approval** in the US
- **Additional orders** from Unimedica Pharma
- **Continued expansion** in the US
- **Publications** in scientific journals
- **Expansion** in selected countries ROW
- **The success of Zeqmelit®** is a top priority – it lays the foundation for further innovative medicines

Global commercialisation strategy

Launch in the Nordic region: Sales started in Sweden, Norway, Finland and Denmark

Additional approvals: Approval in the European countries and in the US, as well as in selected markets ROW

Distributors and licensees: With carefully selected local commercial partners, we will ensure to efficiently scale up distribution in selected markets

Agreement: First commercial agreement signed

Order: Three orders received

Production: Volume production of the drug has been ensured

Expansion into new markets – process

Business model

- Commercialize Zeqmelit® via global network of distributors/licensees
- Capital-light business model

Successful launch in the Nordics a springboard to new markets

Partner Agreement

- Distribution agreements (for example Unimedica Pharma)
- License agreement

Careful selection process

- The right partner for the right market



Investment case

1. Innovative product – clear clinical benefit

Zeqmelit® is a fast-dissolving oral film – easy to carry and easy to use – that addresses a large patient need for acute and severe allergic reactions.

2. Low development risk – Zeqmelit® approved

Zeqmelit® is approved for sale in Sweden, Norway, Finland and Denmark with regulatory approvals and agreements with distributors.

3. Sales started – Sweden, Norway, Finland & Denmark

Zeqmelit® has been available in pharmacies in Sweden, Norway and Finland since the autumn of 2024 and since this summer in Denmark.

4. Large market – over USD 3 billion

Around 30% of the world's population suffers from allergic symptoms. The potential market for Zeqmelit® is estimated to be worth more than USD 3 billion.

5. Competent team – Experienced board

The management and the Board of Directors have a broad and deep experience in commercializing new drugs.

Board of Directors and CEO



Ebba Fåhraeus
Chairperson

Born: 1963. Elected in 2018. Education: Master of Science in Business and Economics from the Stockholm School of Economics.

Deep and broad experience of business development, growth strategies and marketing in both listed and unlisted Life Science companies.

Holdings: 1,779,508 shares.



Helen Ljungdahl Round
Board member

Born: 1964. Elected in 2025. Education: Bachelor's degree in economics from Uppsala University and MBA from Thunderbird, USA.

Extensive experience from Life Science ranging from pre-clinical biotech start-ups to listed MedTech companies with a focus on growth in the US market.

Holdings: 0 shares.




Jan Poulsen
Board member

Elected in 2025.

Extensive experience of running, developing and creating growth in companies in a number of industries and countries within the EU. More than 25 years of experience investing in the biotech and medtech sector and is involved in several companies that focus on expansion and growth in the US. Jan can also contribute with a broad network towards investors and relevant industry knowledge.

Holdings: 17,031,342 shares via Life Science Invest Fund 1 Aps.



Anna Eriksrud
Board member

Born: 1958. Elected in 2017. Education: International MBA from Uppsala University.

Background as an entrepreneur in healthcare with over 25 years of experience from the medical and pharmaceutical sectors, mainly from Q-Med and Pharmacia. She has run Apoteksamariten and led the launch of global brands both in Europe and the US.

Holdings: 145,569 shares.



Göran Tornling
Board member

Born: 1947. Elected in 2021. Education: M.D., Ph.D., Professor Emeritus of Pulmonary Medicine at Karolinska Institutet, Stockholm.

More than 20 years of experience from all phases of clinical development in the pharmaceutical industry and has held senior positions at AstraZeneca, Orexo and a number of smaller life science companies.

Holdings: 104,160 shares.



Jonas Jönmark
CEO

Born: 1971. CEO since 2020. Education: MSc in Business and Economics from Lund University.

More than 20 years of experience from senior positions and in the Life Science sector. Worked at large international pharmaceutical companies such as Pfizer, Astellas Pharma and AstraZeneca, as well as smaller start-up companies such as LifeScience Support and Alteo Medical. Broad experience from international business development, global product launches and creating strong sales growth.

Holdings: 4,362,311 shares.

Thanks!

